Lakewood-Amedex Biotherapeutics Redeems All Remaining Preferred Shares for $1.27 Million

PUBT · 5d ago
Lakewood-Amedex Biotherapeutics Redeems All Remaining Preferred Shares for $1.27 Million
  • Lakewood-Amedex Biotherapeutics today completed redemption of all 127,097 remaining Series C Convertible Preferred Stock shares for $1.27 million.
  • Cash on hand funded the redemption under a November 2, 2026, agreement with Shakawe Capital.
  • No preferred stock or indebtedness for borrowed money remains outstanding.
  • The redemption eliminates potential dilution from Series C Preferred Stock conversions and removes associated financing restrictions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY89502) on November 05, 2026, and is solely responsible for the information contained therein.